Cancer Genetics Announces Participation at the 22nd Annual Rodman & Renshaw Global Investment Conference
September 10 2020 - 8:00AM
Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in
drug discovery and preclinical oncology and immuno-oncology
services, today announced it will present at the 22nd Annual Rodman
& Renshaw Global Investment Conference sponsored by H.C.
Wainwright & Co., LLC. The conference is being
held virtually from September 14-16, 2020.
Event: 22nd Annual Rodman & Renshaw Global Investment
ConferenceDate: September 16, 2020Time: 11:30am
ETConference Details: www.rodmanevents.com
Cancer Genetics’ management team will provide an
overview of the Company's business and scientific advancements
during the live presentation and will be available to participate
in one-on-one virtual meetings with investors who are registered to
attend the conference. Management will also be available for
virtual investor meetings outside the conference.
If you are an institutional investor and would
like to attend the Company’s presentation, please click on the
following link (www.rodmanevents.com) to register for the Rodman
& Renshaw conference. Once your registration is confirmed, you
will be prompted to log into the conference website and also be
able to request a one-on-one meeting with the Company.
For further information about attending the
Company’s presentation or to book an individual appointment with
Cancer Genetics’ management, please contact Jennifer K. Zimmons,
Ph.D., at +1 917.214.3514 or jzimmons@zimmonsic.com.
To see the full list of upcoming events where
the Company intends to present or participate, please visit Cancer
Genetics’ web site under Events & Presentations.
ABOUT CANCER GENETICS
Through its vivoPharm subsidiary, the Cancer
Genetics offers proprietary preclinical test systems supporting
clinical diagnostic offerings at early stages, valued by the
pharmaceutical industry, biotechnology companies and academic
research centers. The Company is focused on precision and
translational medicine to drive drug discovery and novel therapies.
vivoPharm specializes in conducting studies tailored to guide drug
development, starting from compound libraries and ending with a
comprehensive set of in vitro and in vivo data and reports, as
needed for Investigational New Drug filings. vivoPharm operates in
The Association for Assessment and Accreditation of Laboratory
Animal Care International (AAALAC) accredited and GLP compliant
audited facilities. For more information, please visit
www.cancergenetics.com.
For more information, please visit or follow CGI
at:
Internet: www.cancergenetics.com
Twitter: @Cancer_Genetics
Forward Looking Statements:
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements pertaining to Cancer Genetics
Inc.’s expectations regarding future financial and/or operating
results, and potential for our services, future revenues or growth,
or the potential for future strategic transactions in this press
release constitute forward-looking statements.
Any statements that are not historical fact
(including, but not limited to, statements that contain words such
as “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in our
attempts to adapt to the global coronavirus pandemic, achieve
profitability by increasing sales of our pre-clinical services,,
maintain our existing customer base and avoid cancellation of
customer contracts or discontinuance of trials, raise capital to
meet our liquidity needs, properly evaluate strategic options, and
other risks discussed in the Cancer Genetics, Inc. Form 10-K for
the year ended December 31, 2019 and Form 10-Q for the quarter
ended June 30, 2020, along with other filings with the Securities
and Exchange Commission. These forward-looking statements speak
only as of the date hereof. Cancer Genetics, Inc. disclaims any
obligation to update these forward-looking statements.
Investor Contacts: Jennifer K. Zimmons.
Ph.D.Investor RelationsZimmons International Communications,
Inc.Email: jzimmons@zimmonsic.comPhone: +1.917.214.3514
###
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Sep 2023 to Sep 2024